Last viewed:
CGEM
Prices are updated after-hours
CGEM
|
$17.84
3.0%
2.91%
1.3M
|
(0.0% 1d)
(11.7% 1m)
(65.7% 1y)
(0.0% 2d)
(0.0% 3d)
(3.9% 7d)
(Infinity%
volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 768,291,107
https://www.cullinanoncology.com
Sec
Filling
|
Patents
| 24 employees
(US) Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.
cancer
ycombinator
add to watch list
Paper trade
email alert is off
Press-releases
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Published: 2024-04-16
(Crawled : 11:00)
- globenewswire.com
CGEM
|
$17.84
3.0%
2.91%
1.3M
|
| 0.7%
| O: 15.52%
H: 3.77%
C: -12.83%
expansion
therapeutics
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Published: 2024-04-16
(Crawled : 11:00)
- globenewswire.com
CGEM
|
$17.84
3.0%
2.91%
1.3M
|
| 0.7%
| O: 15.52%
H: 3.77%
C: -12.83%
MS
|
News
0
d
|
$90.08
1.06%
-0.28%
9.5M
|
Finance
| 2.6%
| O: 2.98%
H: 0.0%
C: 0.0%
million
therapeutics
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-14
(Crawled : 11:00)
- globenewswire.com
CGEM
|
$17.84
3.0%
2.91%
1.3M
|
| 2.0%
| O: -1.12%
H: 3.57%
C: 0.71%
year
update
financial
results
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
Published: 2024-03-01
(Crawled : 12:00)
- globenewswire.com
CGEM
|
$17.84
3.0%
2.91%
1.3M
|
| -6.23%
| O: 3.41%
H: 0.42%
C: -3.09%
cln-619
fda
drug
clearance
application
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2023-12-18
(Crawled : 22:00)
- globenewswire.com
CGEM
|
$17.84
3.0%
2.91%
1.3M
|
| 89.7%
| O: -0.33%
H: 4.62%
C: 0.88%
conference
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
Published: 2023-12-14
(Crawled : 21:00)
- globenewswire.com
CGEM
|
$17.84
3.0%
2.91%
1.3M
|
| 103.53%
| O: 1.18%
H: 2.56%
C: -4.3%
cln-617
first
protein
trial
il-12
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Published: 2023-11-08
(Crawled : 12:00)
- globenewswire.com
CGEM
|
$17.84
3.0%
2.91%
1.3M
|
| 75.66%
| O: 0.2%
H: 3.95%
C: 0.61%
update
financial
results
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
Published: 2023-11-03
(Crawled : 16:00)
- globenewswire.com
CGEM
|
$17.84
3.0%
2.91%
1.3M
|
| 84.26%
| O: 2.13%
H: 4.38%
C: 3.33%
Cullinan Oncology to Participate in Upcoming Investor Conferences
Published: 2023-10-30
(Crawled : 12:00)
- globenewswire.com
CGEM
|
$17.84
3.0%
2.91%
1.3M
|
| 105.46%
| O: 1.42%
H: 2.34%
C: 1.64%
Cullinan Oncology to Participate in Upcoming Investor Conferences - October 30, 2023
Published: 2023-10-30
(Crawled : 13:00)
- biospace.com/
CGEM
|
$17.84
3.0%
2.91%
1.3M
|
| 105.46%
| O: 1.42%
H: 2.34%
C: 1.64%
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount